Form 4: Exelixis Director Receives Equity Grant

Director Tomas J. Heyman was granted 8,367 restricted stock units as part of the Exelixis, Inc. 2017 Equity Incentive Plan.

Summary

• Director Tomas J. Heyman acquired 8,367 restricted stock units (RSUs) on May 27, 2026.
• The RSUs were granted under the Exelixis, Inc. 2017 Equity Incentive Plan.
• The grant has a zero-dollar acquisition price.
• Following this transaction, the director's total beneficial ownership is 50,649 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant impact on the company's financial outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard equity incentive grant consistent with corporate governance practices.

Negatives

• None identified.

Risks

• Vesting is subject to the Reporting Person's continuous service through May 27, 2027.

Future Outlook

The RSUs are scheduled to vest 100% on May 27, 2027, provided the director maintains continuous service with the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard component of corporate governance in the biotechnology sector, intended to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The grant structure follows standard industry practices for mid-to-large cap biotech firms.
• Vesting schedules of one year for director equity are common among peers such as Amgen or Gilead Sciences.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• Vesting of the RSU grant on May 27, 2027.

Key Dates

Keywords

Exelixis, EXEL, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation